Clinical Research Directory
Browse clinical research sites, groups, and studies.
Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Summary
This randomized trial is comparing a standard neoadjuvant chemotherapy with a genomic driven chemotherapy in patients with breast cancer.
Official title: Randomized Trial Comparing Standard Neoadjuvant Chemotherapy to Genomic Driven Chemotherapy Regimen in Patients With Breast Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
303
Start Date
2009-01
Completion Date
2011-12
Last Updated
2026-08-17
Healthy Volunteers
No
Conditions
Interventions
Chemotherapy
4 cycles FEC followed by 4 cycles docetaxel
Genomic driven chemotherapy
High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
Locations (1)
Institut Gustave Roussy
Villejuif, France